Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biktarvy vs dolutegravir + Truvada in HIV-1 and HBV coinfection (CTR20191588)
CTR20191588Phase 3Completed
- Sponsor
- Gilead Sciences
- Start
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of bictegravir + emtricitabine + tenofovir alafenamide in human immunodeficiency virus infection (HIV), hepatitis B (HBV), sponsored by Gilead Sciences. Started Oct 2019; status: completed.
02
Drugs
bictegravir + emtricitabine + tenofovir alafenamide
03
Conditions
human immunodeficiency virus infection (HIV)hepatitis B (HBV)
Beyond the preview
Go deeper on CTR20191588.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20191588.